A phase 2 study, led by Thomas W. Ferkol, MD, at the UNC School of Medicine, demonstrates safety and efficacy of idrevloride with hypertonic saline for treatment of primary ciliary dyskinesia, a rare genetic disorder that can lead to permanent lung damage.
Read the full story here.